An open-label evaluation of the tolerability and safety of Stalevo� (carbidopa, levodopa and entacapone) in Parkinson?s disease patients experiencing wearing-off
William C. Koller(Stanford University), Dee E. Silver, Adrián L. Rabinowicz(Novartis (Switzerland)), M. Guarnieri(Novartis (Switzerland)), Jean Hubble(The Ohio State University)
Cited by 52
Related Papers
Variable expression of Parkinson's disease
|Neurology|1990|1.3k
International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study
|Movement Disorders|2006|1.1k
Mitochondrial Polymorphisms Significantly Reduce the Risk of Parkinson Disease
|The American Journal of Human Genetics|2003|537
High‐frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor
|Annals of Neurology|1997|484